PRELUDE THERAPEUTICS INC Operating Cash Flow
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Cash Flow of -$37.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.57M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.68M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $23.12M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$19.11M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2025 was -$56.30M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2024 was -$102.89M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2023 was -$107.06M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) operating activities for fiscal 2022 was -$83.73M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$37.26M 10-Q · filed 2026-08-11 | -$14.14M derived: sum of 3 quarters · filed 2026-08-11 | -$33.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$21.68M 10-Q · filed 2026-05-12 | $1.43M derived: sum of 2 quarters · filed 2026-05-12 | -$17.68M derived: sum of 3 quarters · filed 2026-05-12 | -$43.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $23.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.00M derived: sum of 2 quarters · filed 2026-03-10 | -$22.07M derived: sum of 3 quarters · filed 2026-08-11 | -$56.30M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$19.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$45.19M derived: sum of 2 quarters · filed 2026-08-11 | -$79.42M 10-Q · filed 2025-11-12 | -$100.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$26.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$60.31M 10-Q · filed 2026-08-11 | -$81.05M derived: sum of 3 quarters · filed 2026-08-11 | -$108.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$34.23M 10-Q · filed 2026-05-12 | -$54.98M derived: sum of 2 quarters · filed 2026-05-12 | -$82.27M derived: sum of 3 quarters · filed 2026-05-12 | -$105.33M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$48.04M derived: sum of 2 quarters · filed 2026-03-10 | -$71.10M derived: sum of 3 quarters · filed 2026-03-10 | -$102.89M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$27.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$50.35M derived: sum of 2 quarters · filed 2025-11-12 | -$82.14M 10-Q · filed 2025-11-12 | -$105.72M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$23.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$54.85M 10-Q · filed 2025-08-14 | -$78.43M derived: sum of 3 quarters · filed 2025-08-14 | -$104.11M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$31.79M 10-Q · filed 2025-05-06 | -$55.37M derived: sum of 2 quarters · filed 2025-05-06 | -$81.05M derived: sum of 3 quarters · filed 2025-05-06 | -$108.72M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$23.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$49.26M derived: sum of 2 quarters · filed 2025-03-10 | -$76.93M derived: sum of 3 quarters · filed 2025-03-10 | -$107.06M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$25.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$53.35M derived: sum of 2 quarters · filed 2024-11-06 | -$83.48M 10-Q · filed 2024-11-06 | -$106.41M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$27.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$57.80M 10-Q · filed 2024-08-12 | -$80.73M derived: sum of 3 quarters · filed 2024-08-12 | -$101.17M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$30.13M 10-Q · filed 2024-05-07 | -$53.06M derived: sum of 2 quarters · filed 2024-05-07 | -$73.50M derived: sum of 3 quarters · filed 2024-05-07 | -$91.97M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$22.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$43.37M derived: sum of 2 quarters · filed 2024-02-15 | -$61.83M derived: sum of 3 quarters · filed 2024-02-15 | -$83.73M 10-K · filed 2024-02-15 |
| 2022-09-30 | -$20.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$38.91M derived: sum of 2 quarters · filed 2023-11-01 | -$60.80M 10-Q · filed 2023-11-01 | -$86.50M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$18.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$40.36M 10-Q · filed 2023-08-03 | -$66.06M derived: sum of 3 quarters · filed 2023-08-03 | -$87.84M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$21.89M 10-Q · filed 2023-05-08 | -$47.60M derived: sum of 2 quarters · filed 2023-05-08 | -$69.37M derived: sum of 3 quarters · filed 2023-05-08 | -$89.28M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$25.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$47.48M derived: sum of 2 quarters · filed 2023-03-15 | -$67.39M derived: sum of 3 quarters · filed 2023-03-15 | -$83.53M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$21.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$41.69M derived: sum of 2 quarters · filed 2022-11-14 | -$57.83M 10-Q · filed 2022-11-14 | -$72.68M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$19.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$36.05M 10-Q · filed 2022-08-09 | -$50.90M derived: sum of 3 quarters · filed 2022-08-09 | -$63.41M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$16.14M 10-Q · filed 2022-05-10 | -$30.99M derived: sum of 2 quarters · filed 2022-05-10 | -$43.50M derived: sum of 3 quarters · filed 2022-05-10 | -$52.40M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$27.35M derived: sum of 2 quarters · filed 2022-03-17 | -$36.26M derived: sum of 3 quarters · filed 2022-03-17 | -$46.18M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$21.41M derived: sum of 2 quarters · filed 2021-11-12 | -$31.33M 10-Q · filed 2021-11-12 | -$39.80M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$18.82M 10-Q · filed 2021-08-12 | -$27.29M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$9.92M 10-Q · filed 2021-05-11 | -$18.39M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$25.66M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$17.20M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |